EP3821911A4 - Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé - Google Patents
Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé Download PDFInfo
- Publication number
- EP3821911A4 EP3821911A4 EP19833361.9A EP19833361A EP3821911A4 EP 3821911 A4 EP3821911 A4 EP 3821911A4 EP 19833361 A EP19833361 A EP 19833361A EP 3821911 A4 EP3821911 A4 EP 3821911A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- doxorubicin
- drug
- preparation
- nucleic acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810765976 | 2018-07-12 | ||
CN201810766003 | 2018-07-12 | ||
PCT/CN2019/095766 WO2020011248A1 (fr) | 2018-07-12 | 2019-07-12 | Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3821911A1 EP3821911A1 (fr) | 2021-05-19 |
EP3821911A4 true EP3821911A4 (fr) | 2022-03-09 |
Family
ID=69142279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19833361.9A Pending EP3821911A4 (fr) | 2018-07-12 | 2019-07-12 | Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220409742A1 (fr) |
EP (1) | EP3821911A4 (fr) |
JP (1) | JP7267416B2 (fr) |
KR (1) | KR102656600B1 (fr) |
AU (1) | AU2019302604B2 (fr) |
TW (1) | TWI743518B (fr) |
WO (1) | WO2020011248A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020064017A1 (fr) * | 2018-09-30 | 2020-04-02 | 百药智达(北京)纳米生物技术有限公司 | Médicament nanoporteur d'acide nucléique, son procédé de préparation, composition pharmaceutique associée, et utilisation correspondante |
US20220047617A1 (en) * | 2018-10-16 | 2022-02-17 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof |
CN111920947B (zh) * | 2020-08-17 | 2022-09-13 | 福州大学 | 一种花菁染料介导的核酸/抗癌药物复合物的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170372A2 (fr) * | 2011-06-08 | 2012-12-13 | University Of Cincinnati | Domaine de jonction multivalente d'arnp pour l'utilisation dans des nanoparticules multivalentes stables d'arn |
WO2016145003A1 (fr) * | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Nanoparticules d'arn pour le traitement du cancer gastrique |
WO2017147557A1 (fr) * | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Oklahoma | Nouvelles jonctions trois voies d'arnp |
WO2020064017A1 (fr) * | 2018-09-30 | 2020-04-02 | 百药智达(北京)纳米生物技术有限公司 | Médicament nanoporteur d'acide nucléique, son procédé de préparation, composition pharmaceutique associée, et utilisation correspondante |
WO2020078216A1 (fr) * | 2018-10-19 | 2020-04-23 | 百药智达(北京)纳米生物技术有限公司 | Médicament nanoporteur d'acide nucléique et procédé de préparation associé |
WO2020078219A1 (fr) * | 2018-10-16 | 2020-04-23 | 百药智达(北京)纳米生物技术有限公司 | Médicament à nanosupport d'acide nucléique, procédé de préparation associé et composition pharmaceutique et application correspondantes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5386020A (en) * | 1991-01-10 | 1995-01-31 | New York University | Multiply connected, three-dimensional nucleic acid structures |
US5278051A (en) * | 1991-12-12 | 1994-01-11 | New York University | Construction of geometrical objects from polynucleotides |
JP2003522524A (ja) * | 1999-11-13 | 2003-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 高次核酸型構造体 |
-
2019
- 2019-07-12 EP EP19833361.9A patent/EP3821911A4/fr active Pending
- 2019-07-12 WO PCT/CN2019/095766 patent/WO2020011248A1/fr unknown
- 2019-07-12 JP JP2021524092A patent/JP7267416B2/ja active Active
- 2019-07-12 AU AU2019302604A patent/AU2019302604B2/en active Active
- 2019-07-12 KR KR1020217004271A patent/KR102656600B1/ko active IP Right Grant
- 2019-07-12 US US17/259,201 patent/US20220409742A1/en active Pending
- 2019-07-12 TW TW108124772A patent/TWI743518B/zh active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170372A2 (fr) * | 2011-06-08 | 2012-12-13 | University Of Cincinnati | Domaine de jonction multivalente d'arnp pour l'utilisation dans des nanoparticules multivalentes stables d'arn |
WO2016145003A1 (fr) * | 2015-03-09 | 2016-09-15 | University Of Kentucky Research Foundation | Nanoparticules d'arn pour le traitement du cancer gastrique |
WO2017147557A1 (fr) * | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Oklahoma | Nouvelles jonctions trois voies d'arnp |
WO2020064017A1 (fr) * | 2018-09-30 | 2020-04-02 | 百药智达(北京)纳米生物技术有限公司 | Médicament nanoporteur d'acide nucléique, son procédé de préparation, composition pharmaceutique associée, et utilisation correspondante |
EP3858846A1 (fr) * | 2018-09-30 | 2021-08-04 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Médicament nanoporteur d'acide nucléique, son procédé de préparation, composition pharmaceutique associée, et utilisation correspondante |
WO2020078219A1 (fr) * | 2018-10-16 | 2020-04-23 | 百药智达(北京)纳米生物技术有限公司 | Médicament à nanosupport d'acide nucléique, procédé de préparation associé et composition pharmaceutique et application correspondantes |
EP3926047A1 (fr) * | 2018-10-16 | 2021-12-22 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Médicament à nanosupport d'acide nucléique, procédé de préparation associé et composition pharmaceutique et application correspondantes |
WO2020078216A1 (fr) * | 2018-10-19 | 2020-04-23 | 百药智达(北京)纳米生物技术有限公司 | Médicament nanoporteur d'acide nucléique et procédé de préparation associé |
EP3851533A1 (fr) * | 2018-10-19 | 2021-07-21 | Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. | Médicament nanoporteur d'acide nucléique et procédé de préparation associé |
Non-Patent Citations (2)
Title |
---|
WU DANDAN ET AL: "DNA nanostructure-based drug delivery nanosystems in cancer therapy", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 533, no. 1, 18 September 2017 (2017-09-18), pages 169 - 178, XP085228334, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2017.09.032 * |
ZENG YUN ET AL: "Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures", JOURNAL OF MATERIALS CHEMISTRY. B, vol. 6, no. 11, 21 March 2018 (2018-03-21), GB, pages 1605 - 1612, XP055881837, ISSN: 2050-750X, DOI: 10.1039/C7TB03223D * |
Also Published As
Publication number | Publication date |
---|---|
KR20210031494A (ko) | 2021-03-19 |
KR102656600B1 (ko) | 2024-04-15 |
TWI743518B (zh) | 2021-10-21 |
AU2019302604A1 (en) | 2021-03-11 |
TW202005638A (zh) | 2020-02-01 |
AU2019302604B2 (en) | 2023-11-02 |
WO2020011248A1 (fr) | 2020-01-16 |
JP7267416B2 (ja) | 2023-05-01 |
JP2021532175A (ja) | 2021-11-25 |
US20220409742A1 (en) | 2022-12-29 |
EP3821911A1 (fr) | 2021-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3835296A4 (fr) | Composé de cétoamide et procédé de préparation, composition pharmaceutique et utilisation associée | |
EP3875458A4 (fr) | Composé de type diphényle, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et ses applications | |
EP3453707A4 (fr) | Dérivé de benzazépine, procédé pour le préparer, composition pharmaceutique et son utilisation | |
EP3459926A4 (fr) | Dérivé de phénylate, procédé pour sa préparation et composition pharmaceutique et utilisations correspondantes | |
EP3719127A4 (fr) | Acide nucléique, composition et conjugué le contenant, procédé de préparation et utilisation | |
EP3974530A4 (fr) | Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation | |
EP3719126A4 (fr) | Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés | |
EP3862348A4 (fr) | Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée | |
EP4035657A4 (fr) | Composition de médicament contenant de l'acétate d'abiratérone, son procédé de préparation et son application | |
EP3903830A4 (fr) | Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation associés | |
EP3718572A4 (fr) | Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation | |
EP3719125A4 (fr) | Acide nucléique, composition et conjugué en contenant, et procédé de préparation et utilisation | |
EP3357491A4 (fr) | Composition pharmaceutique contenant un médicament anionique, et son procédé de préparation | |
EP3858846A4 (fr) | Médicament nanoporteur d'acide nucléique, son procédé de préparation, composition pharmaceutique associée, et utilisation correspondante | |
EP3842534A4 (fr) | Acide nucléique, composition et conjugué contenant un acide nucléique et leur procédé d'utilisation | |
EP3992290A4 (fr) | Acide nucléique, composition pharmaceutique et conjugué contenant un acide nucléique et leur procédé d'utilisation | |
EP3978029A4 (fr) | Acide nucléique, composition et conjugué pharmaceutiques, leur procédé de préparation et leur utilisation | |
EP3714887A4 (fr) | Composition pharmaceutique pour administration topique et procédé de préparation associé | |
EP3950690A4 (fr) | Dérivé pyrrolohétérocyclique, son procédé de préparation et son application en médecine | |
EP3821911A4 (fr) | Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé | |
EP3278799A4 (fr) | Composition pharmaceutique de nanoparticules d'albumine et de docétaxel, procédé de préparation de ladite composition et son utilisation | |
EP3974532A4 (fr) | Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation | |
EP3978609A4 (fr) | Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation | |
EP3686212A4 (fr) | Composé triterpénique pentacyclique et procédé de préparation de celui-ci, composition pharmaceutique et utilisation associées | |
EP3744316A4 (fr) | Composition pharmaceutique ophtalmique, son procédé de préparation et son application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210209 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220204 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/713 20060101ALI20220131BHEP Ipc: C12N 15/11 20060101ALI20220131BHEP Ipc: C12N 15/10 20060101ALI20220131BHEP Ipc: A61K 47/54 20170101AFI20220131BHEP |